|
|
.
See Category: Neoplasms
See Header: Carcinoma in situ of skin of upper limb, including shoulder
ICD-10 (CM) Code and Descriptor
|
D04.61 |
Carcinoma in situ of skin of right upper limb, including shoulder
|
D0461 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 46.47%
|
22.45%
|
10.52%
|
5.52%
|
4.11%
|
3.00%
|
1.98%
|
1.56%
|
1.41%
|
0.93%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for D04.61*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
88305
|
TISSUE EXAM BY PATHOLOGIST |
2,500
|
3,476
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
950
|
952
|
|
11102
|
TANGNTL BX SKIN SINGLE LES |
511
|
511
|
|
17000
|
DESTRUCT PREMALG LESION |
430
|
430
|
|
17262
|
DSTRJ MAL LES T/A/L 1.1-2.0 |
399
|
436
|
|
17003
|
DESTRUCT PREMALG LES 2-14 |
330
|
1,054
|
|
17311
|
MOHS 1 STAGE H/N/HF/G |
243
|
248
|
|
12032
|
INTMD RPR S/A/T/EXT 2.6-7.5 |
242
|
242
|
|
11602
|
EXC TR-EXT MAL+MARG 1.1-2 CM |
232
|
235
|
|
17261
|
DSTRJ MAL LES T/A/L .6-1.0CM |
199
|
217
|
|
11103
|
TANGNTL BX SKIN EA SEP/ADDL |
192
|
270
|
|
11603
|
EXC TR-EXT MAL+MARG 2.1-3 CM |
125
|
129
|
|
17313
|
MOHS 1 STAGE T/A/L |
117
|
119
|
|
17272
|
DSTR MAL LES S/N/H/F/G 1.1-2 |
111
|
130
|
|
88342
|
IMHCHEM/IMCYTCHM 1ST ANTB |
103
|
111
|
|
17110
|
DESTRUCT B9 LESION 1-14 |
103
|
103
|
|
13121
|
CMPLX RPR S/A/L 2.6-7.5 CM |
94
|
94
|
|
77412
|
RADIATION TX DELIVERY COMPLX |
80
|
80
|
|
J3010
|
FENTANYL CITRATE INJECTION |
80
|
110
|
|
J2704
|
INJ, PROPOFOL, 10 MG |
80
|
2,528
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
D04.61 related to the following DRG Codes:
606-607
|
